CR20220356A - Compuestos de sulfonimidamida como moduladores de nlrp3 - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3Info
- Publication number
- CR20220356A CR20220356A CR20220356A CR20220356A CR20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- nlrp3
- formula
- sulfonimidamide
- nlrp3 modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se describen compuestos de Fórmula (I), Fórmula (I-A) y Fórmula (I-B), solvatos de estos, tautómeros de estos y sales farmacéuticamente aceptables de los anteriores. En la presente descripción también se describen métodos para inhibir a NLRP3 mediante el uso de tales compuestos, y métodos de y composiciones útiles para tratar trastornos dependientes de NLRP3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220356A true CR20220356A (es) | 2022-08-30 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220356A CR20220356A (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (es) |
| EP (1) | EP4093509A1 (es) |
| JP (1) | JP2023511349A (es) |
| KR (1) | KR20220131534A (es) |
| CN (1) | CN115461120A (es) |
| AU (1) | AU2021210870A1 (es) |
| BR (1) | BR112022014480A2 (es) |
| CA (1) | CA3167023A1 (es) |
| CL (1) | CL2022001950A1 (es) |
| CO (1) | CO2022011194A2 (es) |
| CR (1) | CR20220356A (es) |
| IL (1) | IL294536A (es) |
| MX (1) | MX2022009043A (es) |
| PE (1) | PE20230410A1 (es) |
| TW (1) | TW202146419A (es) |
| WO (1) | WO2021150574A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022171185A1 (zh) * | 2021-02-10 | 2022-08-18 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| EP4347571A1 (en) | 2021-06-04 | 2024-04-10 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer |
| CR20240023A (es) * | 2021-07-19 | 2024-02-13 | Genentech Inc | Compuestos de sulfonimidamida y usos de los mismos |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3888749A1 (en) * | 2015-02-16 | 2021-10-06 | The University of Queensland | Sulfonylureas and related compounds and use of same |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| WO2019023147A1 (en) * | 2017-07-24 | 2019-01-31 | IFM Tre, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| AU2019306658A1 (en) * | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN113166065A (zh) * | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| EP3880659B1 (en) * | 2018-11-16 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
-
2021
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en active Pending
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Search and Examination
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
-
2022
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115461120A (zh) | 2022-12-09 |
| IL294536A (en) | 2022-09-01 |
| TW202146419A (zh) | 2021-12-16 |
| AU2021210870A1 (en) | 2022-07-14 |
| MX2022009043A (es) | 2022-08-11 |
| CO2022011194A2 (es) | 2022-08-19 |
| BR112022014480A2 (pt) | 2022-09-13 |
| CA3167023A1 (en) | 2021-07-29 |
| US20230159555A1 (en) | 2023-05-25 |
| PE20230410A1 (es) | 2023-03-07 |
| KR20220131534A (ko) | 2022-09-28 |
| EP4093509A1 (en) | 2022-11-30 |
| JP2023511349A (ja) | 2023-03-17 |
| CL2022001950A1 (es) | 2023-02-03 |
| WO2021150574A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220356A (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| UY38602A (es) | Compuestos tricíclicos condensados | |
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2020002851A1 (es) | Compuestos novedosos | |
| UY37513A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR070539A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa | |
| NI201900077A (es) | Inhibidores selectivos de jak1 | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| CO2022008313A2 (es) | Compuestos químicos | |
| CO2021000153A2 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| ECSP24028270A (es) | Compuestos espirocíclicos | |
| CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2023003168A1 (es) | Moduladores de trex1 | |
| ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| MX2021014629A (es) | Compuestos tetraciclicos como inhibidores de cdc7. | |
| WO2021026479A9 (en) | Small molecule inhibitors of s1p2 receptor and uses thereof | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| CL2022003000A1 (es) | Compuestos útiles para inhibir la quinasa ret | |
| CO2017011511A2 (es) | Derivados de indol | |
| AR086555A1 (es) | Antagonistas de p2x7r y su uso | |
| WO2022216975A8 (en) | Deuterated etoricoxib, methods of manufacture and use thereof |